Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

November 8, 2018

Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference

November 6, 2018

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

October 25, 2018

Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call

October 8, 2018

Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

September 13, 2018

Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

August 28, 2018

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 21, 2018

Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

August 6, 2018

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

July 23, 2018

Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call

July 16, 2018

Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

June 23, 2018

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

June 21, 2018

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

June 20, 2018

Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

June 7, 2018

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

June 6, 2018

Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

June 5, 2018

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018

May 31, 2018

Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders

May 23, 2018

Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018

May 14, 2018

Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees

May 9, 2018

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

May 3, 2018

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

May 2, 2018

Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders

May 1, 2018

Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

May 1, 2018

Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business

May 1, 2018

Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update

April 17, 2018

Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call

April 9, 2018

Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital

March 5, 2018

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

February 15, 2018

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update

February 1, 2018

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call

January 16, 2018

Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

January 2, 2018

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference